Atripla

Type: Product
Name: Atripla
First reported Aug 29 2014 - Updated Aug 29 2014 - 1 reports

Tenofovir and NSAIDs

Cases of acute renal failure after initiation of high dose or multiple non-steroidal anti-inflammatory  drugs have been reported in patients treated with tenofovir disoproxil fumarate and with  risk factors for renal dysfunction. In patients at risk for ... [Published Pharmaceutical Journal - Aug 29 2014]
First reported Aug 26 2014 - Updated Aug 27 2014 - 2 reports

Should Gilead Sciences, inc. Fear This New Competitor Drug?

According to ViiV Healthcare -- GlaxoSmithKline (NYSE: GSKThat creates a significant hurdle for policy makers eager to lower HIV incidence rates and drugmakers eager to boost prescription volume for next-generation therapies.As a result, drugmakers are ... [Published Motley Fool - Aug 26 2014]
First reported Aug 25 2014 - Updated Aug 26 2014 - 6 reports

The Role of Triumeq in HIV Treatment

Joel Gallant, M.D., M.P.H.The approval of Triumeq, the single-tablet coformulation of abacavir , lamivudine and the integrase inhibitor dolutegravir, is an important step forward for antiretroviral therapy. All of the previously approved single-tablet ... [Published The Body - Aug 26 2014]
First reported Aug 25 2014 - Updated Aug 25 2014 - 1 reports

Five things for pharma marketers to know: Monday, August 25

Share this article:Five things for pharma marketers to know: Monday August 25Roche is no longer looking to own Japanese drugmaker Chugai in full. Bloomberg reports that the Swiss company has decided not to scoop up the 38% of shares it does not already ... [Published Medical Marketing And Media - Aug 25 2014]
First reported Aug 22 2014 - Updated Aug 23 2014 - 4 reports

FDA approves ViiV Healthcare's Triumeq tablets for treatment of HIV-1 infection

Published on August 23, 2014 at 2:25 AM · No CommentsViiV Healthcare announced today that the US Food and Drug Administration (FDA) has approved Triumeq® (abacavir 600mg, dolutegravir 50mg and lamivudine 300mg) tablets for the treatment of HIV-1 infection. ... [Published News-Medical.Net - Aug 23 2014]
First reported Aug 14 2014 - Updated Aug 15 2014 - 1 reports

HIV and Medicare, Even if you Aren't HIV Positive

Should you have to pay for treatment for a condition you don't have? How about Medicare? Would you expect Medicare to pay for treatment for a Medicare beneficiary if they are not sick? Two years ago, the prescription drug program, known as Part D, ... [Published InsureBlog - Aug 14 2014]
First reported Aug 14 2014 - Updated Aug 14 2014 - 1 reports

Ugandans Starting HIV Treatment Early Fare Very Well

Ugandans with HIV who begin treatment with higher CD4 counts can do quite well on therapy, countering beliefs that guidelines calling for earlier treatment may not play out well in practice, aidsmap reports. Publishing their findings in the journal AIDS, ... [Published POZ.com - Aug 14 2014]
Entities: HIV/AIDS, Kaletra, Atripla
First reported Aug 12 2014 - Updated Aug 12 2014 - 1 reports

An integrase inhibitor such as raltegravir may reduce immune activation in early therapy

Facebook Twitter Google + Email PrintA new study shows that an initial early treatment using the integrase inhibitor raltegravir (Isentress) leads to less immune activation in people with HIV than initial treatment with other drugs, including those ... [Published Project Inform - Aug 12 2014]
First reported Aug 06 2014 - Updated Aug 06 2014 - 1 reports

Memory, thought processes and concentration

Two studies have reported reassuring news aboutneurocognitive impairment – in other words, problems with memory,concentration, thinking ability, fine motor skills or visual-spatial abilities.In the 1980s, dementia was common in people with veryadvanced ... [Published Aidsmap - Aug 06 2014]
Entities: HIV/AIDS, Memory, Drugs, Sustiva
First reported Aug 01 2014 - Updated Aug 01 2014 - 1 reports

Raltegravir Regimen More Durable, Atazanavir Less Durable, Than Single-Tablet Atripla

20th International AIDS ConferenceJuly 20-25, 2014Melbourne, Australia Tweet 20th International AIDS Conference, July 20-25, 2014, Melbourne IAC: Economic Burden of Adverse Events Associated With HIV Antiretroviral Therapy in the United States (07/30/14) ... [Published National AIDS Treatment Advocacy Project - Aug 01 2014]
First reported Aug 01 2014 - Updated Aug 01 2014 - 1 reports

Are Side Effects the Price to Pay for Having HIV?

Part of the Series Other Sides of HIV : People Taking HIV Meds Share Stories About Side EffectsI became infected in early 2003 and I was diagnosed with HIV in June 2005. I didn't start taking meds until February 2010 and my doctor, of course, prescribed ... [Published The Body - Aug 01 2014]
First reported Jul 24 2014 - Updated Jul 24 2014 - 4 reports

Gilead beats forecasts as Sovaldi sales soar

US anti-virals specialist biotech firm Gilead Sciences (Nasdaq: GILD) has reported surging second-quarter 2014 sales and profits, boosted by a sharp quarter on quarter rise in revenues from its latest hepatitis C drug Sovaldi (sofosbuvir) and exceed analysts’ ... [Published Pharma Letter - Jul 24 2014]

Quotes

"We rate SUNEDISON INC (SUNE) a SELL. This is driven by a number of negative factors, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, poor profit margins, weak operating cash flow and feeble growth in its earnings per share."

More Content

All (49) | News (45) | Reports (0) | Blogs (4) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Tenofovir and NSAIDs [Published Pharmaceutical Journal - Aug 29 2014]
Goldman Sachs' 50 Stocks That Matter Most to He... [Published TheStreet.com - Aug 27 2014]
Goldman Sachs' 50 Stocks That Matter Most to He... [Published The Street Latest - Aug 27 2014]
Should Gilead Sciences, inc. Fear This New Comp... [Published Motley Fool - Aug 26 2014]
GSK share price: ViiV’s combined HIV treatment ... [Published Invezz - Aug 26 2014]
ViiV bags US approval for HIV blockbuster-in-wa... [Published PMLive - Aug 26 2014]
The Role of Triumeq in HIV Treatment [Published The Body - Aug 26 2014]
FDA Approves New HIV Drug [Published Pharmacy Practice News - Aug 25 2014]
Five things for pharma marketers to know: Monda... [Published Medical Marketing And Media - Aug 25 2014]
FDA Approves Triumeq (Abacavir/Dolutegravir/Lam... [Published PT Community - Aug 25 2014]
FDA Approves New Single-Tablet HIV Regimen, Tri... [Published POZ.com - Aug 25 2014]
ViiV Healthcare gains FDA approval for HIV drug... [Published Pharma Letter - Aug 25 2014]
Shionogi : ViiV Healthcare Receives FDA approva... [Published 4 Traders - Aug 25 2014]
ViiV gets FDA green light for HIV triple combo [Published Pharma Times - Aug 25 2014]
SHIONOGI : ViiV Healthcare Receives FDA approva... [Published 4 Traders - Aug 25 2014]
FDA approves ViiV Healthcare's Triumeq tablets ... [Published News-Medical.Net - Aug 23 2014]
Triumeq (Tivicay + Epzicom) Becomes Newest Sing... [Published The Body PRO - Aug 22 2014]
FDA OKs New Triple-Combination Pill (Triumeq) f... [Published General Medicine eJournal - Aug 22 2014]
Another full-regimen HIV pill enters the market... [Published Project Inform - Aug 22 2014]
ViiV Healthcare's Triumeq approved for the trea... [Published FirstWord Pharma - Aug 22 2014]
GlaxoSmithKline's ViiV wins FDA nod for three-i... [Published FierceBiotech - Aug 22 2014]
Glaxo, Pfizer’s ViiV Wins Approval for HIV Comb... [Published Bloomberg - Aug 22 2014]
Stock Update (NASDAQ:GILD): UK cost body backs ... [Published Jutia Group - Aug 15 2014]
HIV and Medicare, Even if you Aren't HIV Positive [Published InsureBlog - Aug 14 2014]
Ugandans Starting HIV Treatment Early Fare Very... [Published POZ.com - Aug 14 2014]
An integrase inhibitor such as raltegravir may ... [Published Project Inform - Aug 12 2014]
HIV/AIDS: What New Treatment Options Are Availa... [Published BlackDoctor.org - Aug 08 2014]
Court Report -- Part II: August 2014 [Published JD Supra - Aug 07 2014]
Memory, thought processes and concentration [Published Aidsmap - Aug 06 2014]
Court Report - August 2014 [Published JD Supra - Aug 05 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
HIV and Medicare, Even if you Aren't HIV Positive [Published InsureBlog - Aug 14 2014]
Should you have to pay for treatment for a condition you don't have? How about Medicare? Would you expect Medicare to pay for treatment for a Medicare beneficiary if they are not sick? Two years ago, the prescription drug program, known as Part D, ...
Why Gilead Sciences Is a Must-Own Stock [Published Wall St. Cheat Sheet - Jun 30 2014]
Source: Thinkstock Gilead Sciences Inc . ( NASDAQ:GILD ) is one of my top choices for any stocks moving forward through 2014 into 2015. This company is a behemoth of a biopharmaceutical company. It designs, discovers, develops, and commercializes ...
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - May 12 2014]
Gilead Sciences: What Happened Today? [Published BARRONS.com Stocks To Watch Today - Mar 07 2014]
Shares of Gilead Sciences (GILD) fell 3.6% today, and the experts I spoke with said that they didn’t see a catalyst for the drop, one that dragged the entire biotech sector down with it. Now there are two possibilities. StreetInsider.com and the Fly On ...
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.